Literature DB >> 23111170

DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.

Mingshun Zhang1, Lu Zhang, Chunhua Zhang, Kunxue Hong, Yiming Shao, Zuhu Huang, Shixia Wang, Shan Lu.   

Abstract

Previously, we have shown that DNA prime-protein boost is effective in eliciting neutralizing antibodies (NAb) against randomly selected HIV-1 isolates. Given the genetic diversity of HIV-1 viruses and the unique predominant subtypes in different geographic regions, it is critical to test the DNA prime-protein boost approach against circulating viral isolates in key HIV endemic areas. In the current study, the same DNA prime-protein boost vaccine was used as in previous studies to investigate the induction of NAb responses against HIV-1 clade BC, a major subtype circulating in China. A codon optimized gp120-BC DNA vaccine, based on the consensus envelope (Env) antigen sequence of clade BC, was constructed and a stable CHO cell line expressing the same consensus BC gp120 protein was produced. The immunogenicity of this consensus gp120-BC was examined in New Zealand White rabbits by either DNA prime-protein boost or protein alone vaccination approaches. High levels of Env-specific antibody responses were elicited by both approaches. However, DNA prime-protein boost but not the protein alone immune sera contained significant levels of NAb against pseudotyped viruses expressing HIV-1 BC Env antigens. Furthermore, high frequencies of CD4 binding site-targeted antibodies were found in the DNA prime- protein boost rabbit sera indicating that the positive NAb may be the result of antibodies against conformationally sensitive epitopes on HIV-1 Env. The findings support that DNA prime-protein boost was effective in eliciting NAb against a key HIV-1 virus subtype in China. This result may lead to the development of regional HIV vaccines through this approach.

Entities:  

Keywords:  DNA vaccine; HIV-1; neutralizing antibody; prime-boost; subtype BC

Mesh:

Substances:

Year:  2012        PMID: 23111170      PMCID: PMC3601137          DOI: 10.4161/hv.21648

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  28 in total

1.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Two subtypes of HIV-1 among injection-drug users in southern China.

Authors:  X F Yu; J Chen; Y Shao; C Beyrer; S Lai
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

3.  Cloning and characterization of a virtually full-length HIV type 1 genome from a subtype B'-Thai strain representing the most prevalent B-clade isolate in China.

Authors:  M Graf; Y Shao; Q Zhao; T Seidl; J Köstler; H Wolf; R Wagner
Journal:  AIDS Res Hum Retroviruses       Date:  1998-02-10       Impact factor: 2.205

4.  Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Authors:  Eric A Weaver; Zhongjing Lu; Zenaido T Camacho; Fatiha Moukdar; Hua-Xin Liao; Ben-Jiang Ma; Mark Muldoon; James Theiler; Gary J Nabel; Norman L Letvin; Bette T Korber; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine.

Authors:  Shixia Wang; Diego J Farfan-Arribas; Siyuan Shen; Te-Hui W Chou; Allison Hirsch; Feng He; Shan Lu
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

7.  Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China.

Authors:  X F Yu; J Chen; Y Shao; C Beyrer; B Liu; Z Wang; W Liu; J Yang; S Liang; R P Viscidi; J Gu; G Gurri-Glass; S Lai
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

8.  Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

Authors:  Shixia Wang; James Arthos; John M Lawrence; Donald Van Ryk; Innocent Mboudjeka; Siyuan Shen; Te-Hui W Chou; David C Montefiori; Shan Lu
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Authors:  Shixia Wang; Ranajit Pal; John R Mascola; Te-Hui W Chou; Innocent Mboudjeka; Siyuan Shen; Qin Liu; Stephen Whitney; Timothy Keen; B C Nair; V S Kalyanaraman; Philip Markham; Shan Lu
Journal:  Virology       Date:  2006-04-17       Impact factor: 3.616

10.  Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Authors:  Penny L Moore; Emma T Crooks; Lauren Porter; Ping Zhu; Charmagne S Cayanan; Henry Grise; Paul Corcoran; Michael B Zwick; Michael Franti; Lynn Morris; Kenneth H Roux; Dennis R Burton; James M Binley
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more
  3 in total

1.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

2.  Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques.

Authors:  Qian He; Qunying Mao; Jialu Zhang; Fan Gao; Yu Bai; Bopei Cui; Jianyang Liu; Chaoqiang An; Qian Wang; Xujia Yan; Jinghuan Yang; Lifang Song; Ziyang Song; Dong Liu; Yadi Yuan; Jing Sun; Jincun Zhao; Lianlian Bian; Xing Wu; Weijin Huang; Changgui Li; Junzhi Wang; Zhenglun Liang; Miao Xu
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

Review 3.  Strategies for inducing effective neutralizing antibody responses against HIV-1.

Authors:  Iván Del Moral-Sánchez; Kwinten Sliepen
Journal:  Expert Rev Vaccines       Date:  2019-12-02       Impact factor: 5.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.